A wide range of cancer cell profiling assays is available to support drug discovery, biomarker identification, and therapeutic development. With access to over 100 validated human cancer cell lines across multiple cancer types—including leukemia, lymphoma, melanoma, kidney, colon, lung, prostate, breast, ovarian, and uterine cancers—these assays provide robust evaluation of compound efficacy and mechanism of action.
High-throughput platforms (96- and 384-well formats) enable rapid, reproducible, and cost-effective analysis, delivering meaningful data at scale. From proliferation and apoptosis to cytokine induction and drug combination studies, these assays generate actionable insights that accelerate cancer research and advance precision medicine development.
Proliferation & Growth
MTT/MTS, LDH, SRB, Almar Blue, and luminescent viability assays
Applicable across >100 validated human cancer cell lines
High-throughput: 384- or 96-well formats
Apoptosis & Cell Cycle
Caspase activation assays
Annexin V/PI staining
Additional FACS-based analyses
Throughput: 96-well
Cytokine Induction
Optimized cell viability assays with tailored incubation times
Drug Combination & Timepoints
CalcuSyn analysis for drug combination index and synergy testing
Custom Assays
Fully tailored assay design based on client needs
| Profile | Assay Description | Throughput |
|---|---|---|
|
Proliferation, growth >100 lines of human cancer cells, including:
|
|
|
| Apoptosis, Cell cycle |
|
|
| Cytokine induction | Cell viability assay with optimized incubation time | 96-well |
| Drug combination and timepoints | CalcuSyn analysis for Combination Index | 96-well |
| Custom | Customer defines assay type | 96-well |
This table highlights a diverse panel of cancer cell profiling assays covering cell proliferation, apoptosis, cytokine induction, and drug combination studies. With access to over 100 human cancer cell lines and flexible 96- and 384-well formats, these assays provide robust tools for evaluating compound efficacy and mechanism of action.